Drug · DIN 02539721
RINVOQ
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 7, 2023; first marketed September 7, 2023.
- Drug Identification Number (DIN)
- 02539721
- Company (DIN owner)
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet (Extended-Release)
- Route
- Oral
- Therapeutic class (ATC)
- Upadacitinib L04AF03
- Class
- Human
- Record last updated
- August 7, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| UPADACITINIB | 45 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 21, 2023: NOC 31270Supplement to a New Drug Submission (SNDS) · New indication for moderately to severely active ulcerative colitis. Addition of a 45 mg extended-release tablet strength
Other DINs named RINVOQ
- DIN 02495155 · Marketed
- DIN 02520893 · Marketed